Corporate Board Profile
Tech Score: 8/100
1 mention(s) identify JOSEPH M. LIMBER as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| XOMA Royalty Corp | 2013-04-11 | From January 2003 to July 2003, Mr. Limber was a consultant and interim Chief Executive Officer for Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was the President and Chief Executive Officer of ACLARA BioSciences, Inc. (now Monogram Biosciences, Inc.), a developer of assay technologies and lab-on-a-chip systems for life science research. | Has experience as President and CEO of companies involved in drug discovery tools and assay technologies, including lab-on-a-chip systems, indicating technical and software-related expertise. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-11 | From January 2003 to July 2003, Mr. Limber was a consultant and interim Chief Executive Officer for Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was the President and Chief Executive Officer of ACLARA BioSciences, Inc. (now Monogram Biosciences, Inc.), a developer of assay technologies and lab-on-a-chip systems for life science research. |
| 2014-04-11 | Mr. Limber has successfully developed markets for specialty pharmaceutical products and managed the critical transition from research organization to commercial entity. He holds a B.A. from Duquesne University. |
| 2015-04-10 | Mr. Limber has served as President and Chief Executive Officer of Gradalis, Inc. and other pharmaceutical companies. He holds a B.A. from Duquesne University. |
| 2016-04-08 | Mr. Limber has served as Executive Chairman of ImaginAb, an immune and oncology imaging company developing a pipeline of novel minibodies for treatment monitoring for immuno-oncology therapies and other drugs since January 2016. Prior to that, Mr. Limber served as President and Chief Executive Officer of Gradalis, Inc. and other biotech companies. |
| 2016-09-12 | Joseph M. Limber(5) Includes 105,406 shares of Common Stock issuable upon the exercise of options exercisable as of 60 days after August 29, 2016. |
| 2017-04-05 | Mr. Limber holds a B.A. from Duquesne University. His roles have been primarily executive and managerial in biotech companies. |
| 2018-04-03 | Mr. Limber holds a B.A. from Duquesne University. Mr. Limber brings to the Board his experience in successfully developing markets for specialty pharmaceutical products and managing the critical transition from research organization to commercial entity. |
| 2019-04-05 | Mr. Limber holds a B.A. from Duquesne University. Mr. Limber brings to the Board his experience in successfully developing markets for specialty pharmaceutical products and managing the critical transition from research organization to commercial entity. |
| 2020-04-09 | Mr. Limber holds a B.A. from Duquesne University. Mr. Limber brings to the Board his experience in successfully developing markets for specialty pharmaceutical products and managing the critical transition from research organization to commercial entity. |
| 2021-04-08 | Mr. Limber holds a B.A. from Duquesne University. His experience is in managing pharmaceutical and biotechnology companies. |
| 2022-04-07 | Mr. Limber has served as CEO of several biotech companies and holds a B.A. from Duquesne University with no mention of technical or software background. |
| 2023-04-04 | Mr. Limber holds a B.A. from Duquesne University. Mr. Limber brings to the Board his experience in successfully developing markets for specialty pharmaceutical products and managing the critical transition from research organization to commercial entity. |
| 2024-04-02 | Mr. Limber holds a B.A. from Duquesne University. |
Data sourced from SEC filings. Last updated: 2025-07-01